BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Other Events
Item 8.01Other Events.
On February 6, 2019, BioSig Technologies, Inc. mailed a letter to its shareholders from Kenneth L. Londoner, its Chairman and Chief Executive Officer, describing certain business updates, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Shareholder Letter,February 2019 |
BioSig Technologies, Inc. Exhibit
EX-99.1 2 ex_134531.htm EXHIBIT 99.1 ex_134531.htm Exhibit 99.1 +1 (310) 820-8100 [email protected] LETTER TO SHAREHOLDERS Los Angeles,…
To view the full exhibit click here
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
